The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article.

Overview

For patients with depressive disorders treated with pharmacotherapy, measurement-based care is effective in decreasing symptom severity, promoting remission, and improving medication adherence.


Read the whole article at psychiatrist.com here: 
The Efficacy of Measurement-Based Care for Depressive Disorders: Systematic Review and Meta-Analysis of Randomized Controlled Trials

© Copyright 2021 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Use measurement-based care for patients with depressive disorders treated with pharmacotherapy

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
09/28/2021
Activity expires: 
10/31/2023
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Use measurement-based care for patients with depressive disorders treated with pharmacotherapy

Statement of Need and Purpose

Treatment outcomes for depression are relatively poor in clinical practice, probably due in part to the lack of use of measurement-based care. Data collected over time with the same standardized assessment tools can help track which treatments help patients regain the ability to function at work and home, which treatments do not help, and which residual symptoms need to be targeted. Clinicians need education on how the implementation of routine monitoring strategies for depression may improve patient outcomes.

Release, Expiration, and Review Dates

This educational activity was published in September 2021 and is eligible for AMA PRA Category 1 Credit™ through October 31, 2023. The latest review of this material was September 2021.

Disclosure of Off-Label Usage

The authors have determined that, to the best of their knowledge, no investigational information about pharmaceutical agents or device therapies that is outside US Food and Drug Administration–approved labeling has been presented in this activity.

Funding/Support

This study was supported by the Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) study, funded by the CIHR and the National Natural Sciences Foundation of China (81761128032) through the Global Alliance on Chronic Disease [CIHR Team Grant: GACD Mental Health, GAC-154985; Agreement #01709-000]. Ms Zhu was supported by a Summer Student Research Program (SSRP) award from the UBC Faculty of Medicine. Ms Hong was supported by a Mach-Gaensslen Foundation of Canada Award through the UBC Faculty of Medicine SSRP.

Role of the Sponsor

The sponsors had no role in the design, conduct, interpretation, or publication of this study.

Faculty Affiliation

Maria Zhu, MSc
Department of Psychiatry, University of British Columbia, Vancouver, Canada

Ran Ha Hong, BSc
Department of Psychiatry, University of British Columbia, Vancouver, Canada

Tao Yang, MD, PhD
Shanghai Mental Health Center and Shanghai Jiao Tong University School of Medicine, Shanghai, China

Xiaorui Yang, MD
Shanghai Mental Health Center and Shanghai Jiao Tong University School of Medicine, Shanghai, China

Xing Wang, MD
Shanghai Mental Health Center and Shanghai Jiao Tong University School of Medicine, Shanghai, China

Jing Liu, MHA
Department of Psychiatry, University of British Columbia, Vancouver, Canada

Jill K. Murphy, PhD
Department of Psychiatry, University of British Columbia, Vancouver, Canada

Erin E. Michalak, PhD
Department of Psychiatry, University of British Columbia, Vancouver, Canada

Zuowei Wang, MD, PhD
Hongkou Mental Health Center, Shanghai, China

Lakshmi N. Yatham, MBBS, MBA(Exec)
Department of Psychiatry, University of British Columbia, Vancouver, Canada

Jun Chen, MD, PhD
Shanghai Mental Health Center and Shanghai Jiao Tong University School of Medicine, Shanghai, China

Raymond W. Lam, MD*
Department of Psychiatry, University of British Columbia, Vancouver, Canada

*Corresponding authors: Raymond W. Lam, MD, 2255 Wesbrook Mall, Vancouver, BC, Canada V6T 2A1 (r.lam@ubc.ca).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past 3 years, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the Independent Data Safety and Monitoring Committee for Janssen (Johnson & Johnson) and Novartis; and has served on advisory boards for Eliem and Sage. As an employee of Massachusetts General Hospital (MGH), Dr Freeman works with the MGH National Pregnancy Registry, which receives funding from Alkermes, Aurobindo, AuroMedics, Johnson & Johnson/Janssen, Otsuka, Sage, Sunovion, Supernus, and Teva, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

Dr Michalak has received funding to support patient education initiatives from Otsuka. Dr Yatham has been on speaker/advisory boards for, or has received research grants from Alkermes, AstraZeneca, Bristol-Myers Squibb, the Canadian Network for Mood and Anxiety Treatments (CANMAT), the Canadian Institutes of Health Research (CIHR), Sumitomo Dainippon Pharma (DSP), Eli Lilly, GlaxoSmithKline, Janssen, the Michael Smith Foundation for Health Research, Pfizer, Servier, Sunovion, and the Stanley Foundation. Dr Chen has received honoraria for ad hoc speaking for DSP, Eli Lilly, Pfizer, Lundbeck, Janssen, and Sunovion. Dr Lam has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, CIHR, CANMAT, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, Michael Smith Foundation for Health Research, Mitacs, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Pfizer, Unity Health, and VGH-UBC Hospital Foundation. Ms Zhu, Ms Hong, Ms Liu, Dr T. Yang, Dr X. Yang, Dr Murphy, and Z. Wang have no disclosures.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. There is a $10 processing fee for this activity.